Clinical Trials Browser

Phase 1 × Alpelisib × 90 days × Clear all

NCT05143229 2026-05-01

ASSET

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Phase 1 Recruiting

BreastDermatologic

Breast Neoplasms, Melanoma